- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Social Media
- Background Information
- Media Contact
Leverkusen, July 2015 – The latest edition of Bayer's science magazine research showcases current topics in medical and agricultural research. In the title story "Unleashing the immune response to cancer" scientists from Bayer HealthCare explain their approach to mobilizing the human immune system to enable it to identify and eliminate tumors. The researchers are working with partners from Israel and Heidelberg, Germany to develop novel immunotherapies that are believed to be a promising route to beating cancer.
The special topic "Decoding molecular patterns" shows researchers at Bayer in their guise as molecular detectives. "Metabolomics" is the analysis of the chemical fingerprint of metabolic processes in the body with the aim of identifying new targets for medicinal substances and testing innovative methods to diagnose diseases. It's a field in which there is a lively exchange between pharmaceutical scientists and plant experts at Bayer, because similar processes take place in plants, insects and micro-organisms and this work is enabling new mechanisms of action and the effects of crop protection products to be understood.
Another article in the magazine looks at citrus plantations, the target of a bacterial disease that is threatening harvests worldwide. Experts at Bayer are working on ways of controlling the pathogen that causes the disease and the vector that transmits it.
The new edition of research also contains an article on complex infectious diseases, which continue to be one of the major challenges in animal health. Stimulation of the innate immune system prompts a rapid and effective response to disease-causing pathogens. Bayer's researchers are investigating the potential of this form of immunostimulation as a way of controlling infectious diseases in farm animals more effectively.
Bayer's science magazine features stories researched using journalistic criteria and selected to illustrate how research can improve the lives of humans, animals and plants – fully in keeping with the company's mission statement "Bayer: Science For A Better Life". The texts are designed to appeal to the reader, with explanatory illustrations, attractive photo galleries showing life in the laboratory and out in the field, and interviews with renowned international scientists. They make the approaches and technologies being used today even more accessible.
research, the Bayer scientific magazine, can be ordered free of charge by phone (+49 214/30-57546), fax (+49 214/30-57547) or e-mail (email@example.com).
The online edition of research: Bringing science to life
Bayer's science magazine research is also available online. Go to www.research.bayer.com and immerse yourself in the world of research at Bayer – on your PC, tablet or smartphone. Fascinating animated sequences, videos and numerous photo galleries make science accessible and comprehensible.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. For more information, go to www.bayer.com.
Find more information at www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.